Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Wolfe Research Upgrades SBA Communications to Peer Perform

Wolfe Research Upgrades SBA Communications to Peer Perform

Wolfe Research analyst Andrew Rosivach upgrades SBA Communications (NASDAQ:SBAC) from Underperform to Peer Perform.

byBenzinga Newsdesk

January 25, 2023

1 minute read

Wolfe Research analyst Andrew Rosivach upgrades SBA Communications (NASDAQ:SBAC) from Underperform to Peer Perform.

Investor Sentiment Improves Ahead Of Earnings Results

By Lisa Levin

October 24, 6:27 AM

The CNN Money Fear and Greed index showed some improvement in the investor sentiment.

AAPL

SVB’s Private Bank Unit Reportedly Eyed By Citizens Financial

By Bhavik Nair

March 23, 11:57 PM

Citizens Financial Group Inc (NYSE:CFG) is reportedly constructing a bid to purchase the private banking business of Silicon…

CFG

News

Russian Foreign Ministry Spokeswoman Says Russia Is Open For Diplomacy; The More Washington Encourage Ukraine’s “Bellicose Mood” The Harder To Find Diplomatic Solutions

By Benzinga Newsdesk

October 10, 1:46 PM

- Reuters

RSX

Anaptys Expands Immune Cell Modulator Pipeline With Exclusive License To BDCA2 Modulator Antibody Portfolio From Centessa Pharmaceuticals; Anaptys Will Pay Centessa A One-Time Upfront Cash Payment Of $7M

By Benzinga Newsdesk

November 27, 5:16 PM

Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolio IND filing to support clinical development of ANB101 in autoimmune and inflammatory

ANAB

Wolfe Research Upgrades SBA Communications to Peer Perform

Related Posts

Investor Sentiment Improves Ahead Of Earnings Results

SVB’s Private Bank Unit Reportedly Eyed By Citizens Financial

Russian Foreign Ministry Spokeswoman Says Russia Is Open For Diplomacy; The More Washington Encourage Ukraine’s “Bellicose Mood” The Harder To Find Diplomatic Solutions

Anaptys Expands Immune Cell Modulator Pipeline With Exclusive License To BDCA2 Modulator Antibody Portfolio From Centessa Pharmaceuticals; Anaptys Will Pay Centessa A One-Time Upfront Cash Payment Of $7M